Copy Link Print Information

Fostamatinib disodium hexahydrate

(Synonyms: R788 disodium hexahydrate)
16 Cited Publications
Customer Review

Based on 16 publication(s) in Google Scholar

Fostamatinib (R788) disodium hexahydrate is the oral proagent of the active compound R406. R406 is an orally available and competitive Syk/FLT3 inhibitor with a Ki of 30 nM and an IC50 of 41 nM. R406 also inhibits Lyn (IC50=63 nM) and Lck (IC50=37 nM).

For research use only. We do not sell to patients.

  • Purity: 99.46%
  • CAS No.: 914295-16-2
  • Formula: C23H36FN6Na2O15P
  • Molecular Weight:732.51
  • Storage:

    4°C, sealed storage, away from moisture

    * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

  • Fostamatinib disodium hexahydrate Chemical Structure
    Fostamatinib disodium hexahydrate Chemical Structure
  • Experimental Validation Results for Fostamatinib disodium hexahydrate
  • Experimental Validation Results for Fostamatinib disodium hexahydrate
  • Experimental Validation Results for Fostamatinib disodium hexahydrate
  • Experimental Validation Results for Fostamatinib disodium hexahydrate
  • Experimental Validation Results for Fostamatinib disodium hexahydrate
  • Experimental Validation Results for Fostamatinib disodium hexahydrate
CAS No.: 914295-16-2
Size
Price
Stock
Quantity
Amount: USD 0.00
Please select quantity
or
or

* Please select Quantity before adding items.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download
Other Forms of Fostamatinib disodium hexahydrate:

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
Find Your Local Distributor Your local distributor: Hycultec GmbHHycultec
  • Biological Activity
  • Chemical Information
  • Solvent & Solubility
  • Purity & Documentation
  • References
  • Help & FAQs
You May Still Need
Top Publications Citing

Use of MCE Products

Publications Citing Use of MedChemExpress (MCE) Fostamatinib disodium hexahydrate

More
Customer Validation & Images
Histological Imaging/StainingIn Vivo Efficacy StudyCell Proliferation/Viability AssayWBRT-PCR
  • Cell Proliferation/Viability Assay
  • WB
  • RT-PCR
  • Cell Proliferation/Viability Assay
  • Histological Imaging/Staining
  • In Vivo Efficacy Study
Keywords
MOQ
Minimum order quantity
100 mg

Get Quote In-stock

Other size
Get Quote
Please select quantity
Amount: USD 0.00
Sign in to MedChemExpress Sign In
Register
Sign in to MedChemExpress
Register New Account

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • Fostamatinib disodium hexahydrate Chemical Structure
    Fostamatinib disodium hexahydrate Chemical Structure
    1/16
  • 1/16

    Fostamatinib disodium hexahydrate purchased from MedChemExpress. Usage Cited in: BMC Med. 2024 Mar 5;22(1):96. [Abstract]

    Customer Validation
     CCK-8 assay showed that Fostamatinib (R788, 1.25–20 μM; 5 h) exhibited mild cytotoxicity in a dose-dependent manner.

  • 1/16

    Fostamatinib disodium hexahydrate purchased from MedChemExpress. Usage Cited in: BMC Med. 2024 Mar 5;22(1):96. [Abstract]

    Customer Validation
     Western blotting analysis of p-p65, p-IRF3, and p-TBK1 from THP-1 cells subjected to MSA-2 stimulation and treated with Fostamatini (R788, 10–20 μM) or AMX (100–200 μM). The results showed that R788 significantly inhibited the levels of phosphorylated TBK1 (p-TBK1) and IRF3 (p-IRF3), with no effect on p65 phosphorylation (p-p65), indicating the specific inhibition on TBK1 within TBK1/IRF3 signaling pathway.

  • 1/16

    Fostamatinib disodium hexahydrate purchased from MedChemExpress. Usage Cited in: BMC Med. 2024 Mar 5;22(1):96. [Abstract]

    Customer Validation
     RT-qPCR showed the relative levels (normalized with GAPDH) of IFNB, TNFA, and IL6 from NSC-34 cells treated with Fostamatinib (R788, 1.25–20 μM).

  • 1/16

    Fostamatinib disodium hexahydrate purchased from MedChemExpress. Usage Cited in: Gene. 2020 Jun 20:744:144608. [Abstract]

    Customer Validation
     Cell Counting Kit-8 assay results showing the effect of Fostamatinib (10 μM) on the proliferative capacity of PC-3 cells.

  • 1/16

    Fostamatinib disodium hexahydrate purchased from MedChemExpress. Usage Cited in: Blood Cancer J. 2014 Aug 22;4(8):e240. [Abstract]

    Customer Validation
     Hematoxylin and eosin-stained liver slides and reticulin stained BM slides are shown from one Fostamatinib (R788, 40 mg/kg; oral gavage; twice daily) treated mouse versus control mouse. Arrows show liver infiltrates in the control group, which are absent in the treatment group. The results showed that in the Fostamatinib (R788, 40 mg/kg; oral gavage; twice daily) group, virtually no infiltration of granulocyte and megakaryocyte progenitor cells was observed in the liver.

  • 1/16

    Fostamatinib disodium hexahydrate purchased from MedChemExpress. Usage Cited in: Blood Cancer J. 2014 Aug 22;4(8):e240. [Abstract]

    Customer Validation
     Fostamatinib (R788, 40 mg/kg; oral gavage; twice a day) significantly improved the survival rate of Balb/c mice transplanted with the TEL‑SYK oncogene by inhibiting SYK (Fig. a), effectively reduced the sizes of the spleen and liver (Fig. b), and decreased white blood cell (WBC) counts simultaneously (Fig. c).

  • Fostamatinib disodium hexahydrate